{"name":"Ebrahim S Delpassand","slug":"ebrahim-s-delpassand","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxORDIzQ0VtQlEwUEdXbWp4TzNsaEp2LUgwal83VUpjQlRpRzlzTjhTRFlCN1UzbkduUkVCZmY2MHBpbS1rV0V6WFBLLWFRMUVNVVNTODJ1U1I3emlnNExnX2xaMHZKY0lxeEV6MTFVM2xlaXgxMnVhVFNYN3gzaGNSa0o2bFQwWUo3TFV0QlRRbXZJOTFkWmc?oc=5","date":"2025-10-09","type":"deal","source":"Life Science Leader","summary":"Partnering To Commercialize Radiopharmaceuticals - Life Science Leader","headline":"Partnering To Commercialize Radiopharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE4zcEpFeHozdWQ3TTFaYXQ1cHFZVnVKTnlveDNFZ29IcEZHRjBVRmpKZTJpbHhLeDRhck9aOWhJemFOR1RYcEc2UVEwQjRnLXptREEyNXc4OU9kWTFfTTNQaEV4NUVmVDMydGc?oc=5","date":"2025-09-03","type":"pipeline","source":"Labiotech.eu","summary":"Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand - Labiotech.eu","headline":"Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVh6NDlXc1ZyT0xpalFyZjFEaDdlX3JaTzFFRkNEWjhZbG14MExLcXlKWFN1WmJuSDNuUWlRT1RSYkI4U0pNaDRkYlhiWHJoWVRYU1NGckd5eDlCdzh5Z05VV3FYN0lSdVAtNUxlWUJrTExBWkltdXV1N0U2S1dWWlZ2Q3p0RmJzM2hoaU9jeEZDQmdudGMxV25zekIyMGUxeWZIM01jMGlGTXZhY3R1WEo1eEZWQ3hUakU0?oc=5","date":"2025-06-06","type":"pipeline","source":"Drug Target Review","summary":"Why radiopharmaceuticals are gaining ground in the fight against cancer - Drug Target Review","headline":"Why radiopharmaceuticals are gaining ground in the fight against cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOS2ttWFJ5aEJ3WGIxaTAySGFsYnNud040akZSRzB3MG5kam9Ma2dGXzY2WmdrTXEtclgxdi1ZdUZDbmRWcHBmVmxWZGh3NmtPX2l3dVdMQ2ZNVVlIYUlnVmYzaTZqMDdvZ0dDWHQ2QmRjVVBCMEk0dWRFb3M2TXhKUldweWFOaDBfSDVwMlpnVGluRW4tdENTQ2ltdkM?oc=5","date":"2025-03-13","type":"pipeline","source":"BioSpace","summary":"Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace","headline":"Houston’s Life Sciences Scene Continues Boosting Its Reputation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE56WG5LS0tTMGNBTHBqdEtreHdCQXVMeXd0WjlfclNLWnVTcTcyY1ZjNXFyNjQ0dFdZOEZUT0hCZHlzRnBsSFhQOGp5RHhtWldBUW9tNW9EMDY?oc=5","date":"2023-08-17","type":"pipeline","source":"jnm.snmjournals.org","summary":"Toward Integrated Independence - jnm.snmjournals.org","headline":"Toward Integrated Independence","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxORHRJQ3lkcnlWVFd1TU4xNTVNaWphRzFjemJsendaZjNRQ0V4cXR0d2gyWkRubXhVcEhFZjZPakU3Yy1YbXNnVHo1bndKVHBDdkN2b3QzcWlReWR1MF9BcnljSkplUDVuLUdGMXVDd2pjbk9yaFozWGlxZ3oydEtHMUMzaURZdTcxSURub2lYTk1oblVVblJoN3BQOWE1NG01V185Z2kwdHI2dHhnbUE4NGxRQkEtakotRVhsTGthY05ScVB1dmtYSnlYd3NOYkdEUGVBZGdKWElhSTBFYVV5VG1vUkVMUHBFcElUOEx5ZE5DbnNZUXo2SlZ5ZW1jcmhQYUxVZUJIMG5aaVNWeXhHanpPcXJDNVhSQW9FampaeWFYdDlHN0s4Z2RR?oc=5","date":"2023-02-13","type":"trial","source":"PR Newswire","summary":"Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer - PR Newswire","headline":"Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrat","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5WQzE2V2s4NTRBX0NHYkVwR3N5US02WTY4SG93cTE2YVJScHY3TTVjb1lqTnNMWm1lN2xweENlNnhsb1F0OXJEa2x5QWJSTnlsaW4yX3p3dGk?oc=5","date":"2022-09-01","type":"trial","source":"jnm.snmjournals.org","summary":"Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial - jnm.snmjournals.org","headline":"Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: F","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}